Meanwhile, the high KCNK1 expression group had lower TIDE scores, suggesting a low tumour immune escape potential and a better outcome of immunotherapy for BC patients (p = 5.7e-7; Fig. 10B). This evidence concerns the gene KCNK1 and neoplasm.